Premium
Tendosynovial sarcoma. Clinicopathologic features, treatment, and prognosis
Author(s) -
Brodsky Jeffrey T.,
Burt Michael E.,
Hajdu Steven I.,
Casper Ephraim S.,
Brennan Murray F.
Publication year - 1992
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19920715)70:2<484::aid-cncr2820700217>3.0.co;2-7
Subject(s) - medicine , sarcoma , survival rate , cancer , metastasis , surgery , primary tumor , chemotherapy , thoracotomy , incidence (geometry) , lymph node , pathology , physics , optics
Background . Clinicopathologic features, treatment, and results are reported for 95 tendosynovial sarcomas identified from a prospective sarcoma data base established at Memorial Sloan‐Kettering Cancer Center (MSKCC) in 1982. Methods . Eighty‐five patients had definitive treatment of the primary tumor at MSKCC. Epithelial sarcomas were excluded. Results . The local recurrence rate was 18%. Survival rates were not influenced by either the method of local treatment or the use of chemotherapy. The overall actuarial survival rate was 59% at 5 years (median, 92 months). For 25 patients who had resection of pulmonary metastases, the 5‐year actuarial survival rate was 43% (median, 22 months) from the time of first thoracotomy. Sex, age, tumor site, and histologic subtype (monophasic versus biphasic) were not significant predictors of survival rates. Regional lymph node metastasis occurred in 3%. The incidence of distant metastasis was 49%, with an associated 5‐year survival rate of 31% (median, 33 months). Tumor size was a highly significant prognostic feature, with 5‐year survival rates of 86yo for patients with tumors smaller than 5 cm and 22% for those with tumors larger than 10 cm ( P < 0.00001). Conclusions . Improvement of treatment results for tendosynovial sarcoma will require effective new systemic adjuvant therapeutic strategies. Cancer 1992; 70:484‐489.